Androgen Deprivation Therapy Market Opportunities Are Emerging Beyond Traditional Growth Areas
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Androgen Deprivation Therapy Market Growth From $8.83 Billion In 2026 To $11.1 Billion By 2030 At A CAGR Of 5.9%
The androgen deprivation therapy market has experienced robust expansion in recent years. Projections indicate a rise from $8.31 billion in 2025 to $8.83 billion in 2026, representing a compound annual growth rate (CAGR) of 6.3%. Several factors contributed to this historical growth, including a scarcity of prostate cancer treatment alternatives, dependence on traditional surgical methods, a gradual acceptance of injectable therapies, insufficient patient awareness regarding androgen deprivation therapy, and limited access to more advanced therapeutic options.
The market for androgen deprivation therapy is projected to experience robust expansion in the coming years, reaching $11.1 billion by 2030 with a compound annual growth rate (CAGR) of 5.9%. This forecasted growth is driven by factors such as the creation of new anti-androgen medications, rising financial commitments to gene and immunotherapies, a growing elderly male demographic, the expansion of specialty clinics and hospital oncology departments, and the incorporation of digital monitoring along with telehealth services. Key developments shaping the future include the widespread use of LHRH agonists and antagonists, the growing application of combination treatments and targeted therapies, the increase in minimally invasive surgical options, a heightened emphasis on patient-specific and age-adapted therapies, and improved surveillance and follow-up care for individuals with prostate cancer.
Download A Free Sample Report For Comprehensive Market Insights:
Androgen Deprivation Therapy Market Growth Momentum: Which Factors Are Influencing Demand?
The growing prevalence of prostate cancer is anticipated to drive expansion within the androgen deprivation therapy market over the coming years. Originating in the prostate gland, which is part of the male reproductive system tasked with producing seminal fluid, this disease sees its occurrence rising prominently, largely attributed to extended lifespans since advanced age substantially elevates the susceptibility to its development. Androgen deprivation therapy (ADT) serves as a fundamental treatment option for prostate cancer, functioning to reduce androgen levels that fuel tumor progression, and is commonly applied in advanced or metastatic stages to slow disease advancement. As an example, a January 2025 report from Prostate Cancer UK, a UK-based organization dedicated to prostate cancer research, awareness, and support, revealed that in England, the annual number of prostate cancer diagnoses grew from 50,751 cases in 2022 to 55,033 cases in 2023, reflecting a clear upward trend in yearly incidence. Consequently, the increasing occurrence of prostate cancer is propelling the growth of the androgen deprivation therapy market.
Androgen Deprivation Therapy Market Segments: Where Are The Largest Growth Opportunities?
The androgen deprivation therapy market covered in this report is segmented –
1) By Type: Medicine, Surgery, Other Types
2) By Route Of Administration: Injectable, Oral
3) By Patient Demographics: Men Aged 40-60, Men Aged 61-75, Men Above 75
4) By Application: Prostate Cancer, Other Applications
5) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Medicine: LHRH Agonists, LHRH Antagonists, Anti-Androgens, CYP17 Inhibitors, Steroidal Anti-Androgens, Non-Steroidal Anti-Androgens, Estrogen-Based Therapies, Combination Therapies
2) By Surgery: Bilateral Orchiectomy, Subcapsular Orchiectomy, Simple Orchiectomy
3) By Other Types: Radiopharmaceutical Therapy, Gene Therapy, Immunotherapy, Targeted Therapy, Cryotherapy, High-Intensity Focused Ultrasound (HIFU
Androgen Deprivation Therapy Market Trends Reshaping Industry Growth
Key players in the androgen deprivation therapy (ADT) market are prioritizing the creation of cutting-edge treatments, including oral androgen receptor inhibitors (ARIs), to deliver more convenient, better-tolerated, and effective care for prostate cancer patients. These oral ARIs function as targeted therapies by directly blocking androgen receptor activity within prostate cancer cells, thereby hindering tumor growth and eliminating the need for frequent hormone-suppressing injections administered in clinical settings. A notable example occurred in June 2025, when Bayer AG, a German multinational pharmaceutical firm, secured US Food and Drug Administration (FDA) approval for Nubeqa (darolutamide), an oral ARI intended for use alongside ADT in treating metastatic hormone-sensitive prostate cancer (mHSPC). Engineered to enhance clinical results and patient well-being, Nubeqa works by inhibiting androgen receptor signaling with strong binding affinity, has minimal blood–brain barrier penetration to reduce central nervous system side effects, and was associated with a 46% lower risk of radiological progression or death compared to a placebo combined with ADT, as demonstrated in the Phase III ARANOTE trial.
Androgen Deprivation Therapy Market Major Participants And Competitive Dynamics
Major companies operating in the androgen deprivation therapy market are Johnson & Johnson Services Inc., Astellas Pharma Inc., Ipsen S.A., Ferring Pharmaceuticals SA, Tolmar Pharmaceuticals Inc., Pfizer Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Orion Corporation, Besins Healthcare S.A., Veru Inc., Kintor Pharmaceutical Limited, Foresee Pharmaceuticals Co. Ltd., Lawley Pharmaceuticals Pty Ltd., AbbVie Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Cipla Ltd., Accord Healthcare Ltd., Mylan N.V. (Viatris), Zydus Lifesciences Ltd., Apotex Inc., Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Alvogen Inc., BCN Peptides SA, Chugai Pharmaceutical Co. Ltd., Sumitomo Pharma Co. Ltd.
Access The Complete Androgen Deprivation Therapy Market Report:
Androgen Deprivation Therapy Market Largest Region By Revenue And Market Share
North America was the largest region in the androgen deprivation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the androgen deprivation therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
